The Quantellect read.As of Nov 19, 2026, 21 active firms cover Insmed Inc: 20 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $169.00 to $241.00, a moderate spread. The average target of $202.79 sits 69% above the current $120.03. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.28 next quarter toward $0.66 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS21 active firms
Buy
Strong Buy00%
Buy2095%
Neutral15%
Sell00%
Strong Sell00%
Based on 21 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$202.79
+68.9% upside
Average target across 19 active firms as of Nov 19, 2026 vs $120.03 current
Highest Target$241.00
Average Target$202.79
Lowest Target$169.00
Detailed analyst forecasts for INSM
Showing 1–21 of 21 named analysts shown · 21 active firms in the rating projection
As of Nov 19, 2026, 20 of 21 active firms rate INSM a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
INSM EPS & revenue forecast
EPS · NEXT QUARTER
$-0.28
Range $-0.53 – $-0.06 · 6 analysts · -63% YoY
Next period, 6 analysts expect Insmed Inc to earn $-0.28 a share (range $-0.53 – $-0.06), versus $-0.76 a year earlier. Full-year consensus is $-1.67, growing to $0.66 the year after.
REVENUE · NEXT QUARTER
$625.6M
Range $555.0M – $666.2M · 6 analysts · +104% YoY
Revenue is expected to reach $625.6M (range $555.0M – $666.2M), +104.5% year-over-year. Full-year consensus is $1.9B, rising to $3.0B next year.
Top analysts covering Insmed Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on INSM.
#1
Leonid Timashev
RBC Capital · Rank #27
Buy
$195.00+62.5% to target
Overall win rate
52%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #73
Buy
$220.00+83.3% to target
Overall win rate
45%
+ Follow
#3
Jessica Fye
JP Morgan · Rank #100
Buy
$175.00+45.8% to target
Overall win rate
54%
+ Follow
#4
Vamil Divan
Guggenheim · Rank #211
Buy
$205.00+70.8% to target
Overall win rate
48%
+ Follow
#5
Graig Suvannavejh
Mizuho · Rank #239
Buy
$154.00+28.3% to target
Overall win rate
40%
+ Follow
INSM stock forecast FAQ
What is INSM's average 12-month price target?+
The 19 active firms with a live target average $202.79 for Insmed Inc over the next 12 months, ranging from a $241.00 high to a $169.00 low, as of Nov 19, 2026.
Is INSM stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 21 active firms as of Nov 19, 2026, 20 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for INSM?+
The Street-high target is $241.00 (TD Cowen), and the Street-low is $169.00 (Wells Fargo). The average of all 19 active-firm targets is $202.79.
How many active Wall Street firms cover INSM?+
21 active firms have a recognized rating on Insmed Inc as of Nov 19, 2026, and 19 active firms carry a live 12-month price target.
Who is the most accurate analyst covering INSM?+
Among analysts who currently cover INSM, Leonid Timashev of RBC Capital has the strongest overall Quantellect track record (Rank #27). Their current call is Buy with a $195.00 target.
What is Insmed Inc's projected EPS for next quarter?+
The consensus estimate is $-0.28 per share (range $-0.53 – $-0.06) across 6 analysts. Full-year EPS is projected at $-1.67, rising to $0.66 the following year.
How much revenue is Insmed Inc expected to report next quarter?+
Consensus revenue is $625.6M (range $555.0M – $666.2M). Full-year revenue is projected at $1.9B, growing to $3.0B next year.
Have analysts been upgrading or downgrading INSM lately?+
As of Nov 19, 2026, 20 of 21 active firms rate INSM a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their INSM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.